Objective: To determine the incidence rates of sudden unexpected death in epilepsy (SUDEP) in different epilepsy populations and address the question of whether risk factors for SUDEP have been identified.
This document summarizes information provided in the complete guideline, available at Neurology.org. Appendix e-6, cited in the full guideline (data supplement), is available at Neurology.org.
Sudden unexpected death in epilepsy (SUDEP) is a poorly understood and catastrophic risk of epilepsy.
The sensitive nature of discussions of this infrequent but important risk with patients and families has prompted the need for evidence-based information about SUDEP. The goal of this practice guideline is to examine evidence for the SUDEP incidence rate in epilepsy populations and for prognostic factors for SUDEP occurrence. This in turn will inform an honest and balanced discussion when clinicians counsel people about SUDEP, and provide insight into areas where more clinical research is needed.
Two questions were asked:
1. What is the incidence rate of SUDEP in different epilepsy populations? 2. Are there specific risk factors for SUDEP?
DESCRIPTION OF THE ANALYTIC PROCESS This practice guideline broadly follows the process delineated in the 2004 American Academy of Neurology (AAN) guideline development process manual, 1 with the exception of the processes for formulating conclusions and recommendations, which follow the processes explained in the 2011 AAN guideline development process manual. 2 In 2010, the AAN Guideline Development, Dissemination, and Implementation Subcommittee and the Guidelines Committee of the American Epilepsy Society convened a panel of experts to develop this practice guideline. The guideline panel engaged an independent medical librarian to search the MEDLINE and Embase databases from earliest available article to November 2010. The panel then performed an identical search in April 2015 to include articles published since November 2010. The keywords for both searches were SUDEP or (sudden and [unexplained or unexpected] and death) combined with the traditional medical subheadings (MeSH) for epilepsy (epilepsy/abnormalities or epilepsy/classification or epilepsy/complications or epilepsy/drug effects or epilepsy/drug therapy or epilepsy/epidemiology or epilepsy/ethnology or epilepsy/etiology or epilepsy/ genetics or epilepsy/mortality or epilepsy/physiopathology or epilepsy/prevention and control or epilepsy/therapy) with limits of humans, plus all child: 0-18 years or all adult: 191 years. Literature types were limited to clinical trial; randomized controlled trial; comparative study; controlled clinical trial; evaluation studies; journal article; multicenter study; research support; NIH, extramural, research support; NIH, intramural, research support; non-US gov't, research support; US gov't, non PHS, research support; or US gov't, PHS, validation studies. Finally, the guideline panel specifically searched causes implicated in SUDEP (i.e., cardiac arrhythmias and preictal autonomic dysfunction), where the hypotheses were tested.
This search yielded 1,068 abstracts, all of which were reviewed for relevance by at least 2 panel members working independently of each other; 744 abstracts were not relevant to provide answers to the questions. Of the remaining 324 abstracts, 2 panel members then obtained the full articles and reviewed them independently for inclusion. Reviewed articles were entered into a database application through an online questionnaire. Seventy articles had data for inclusion, and 254 were excluded because they failed to address the questions, employ an adequate SUDEP definition, or use an appropriate epilepsy comparison group in the prognostic studies. The available literature consisted of multiple Class I articles for incidence, and therefore articles rated Class II or lower were excluded because the Class II publications did not address populations not otherwise encompassed by the Class I articles. Several Class I and multiple Class II articles were available for prognostic questions.
Included articles were required to state that the SUDEP definition provided by Nashef, 3 Annegers, 4 and Leestma et al. 5 was used or to describe criteria in accordance with these definitions. These definitions share the following criteria, and the guideline panel included any article that incorporated these criteria in its SUDEP definition: (1) the patient had epilepsy by reasonable criteria without reference to the criteria used for epilepsy; (2) deaths by drowning, trauma, or status epilepticus were excluded; (3) death could have occurred after a witnessed seizure; (4) other competing causes of death were excluded.
The guideline panel used 2 of the AAN's evidencebased schemes to rate articles: the screening criteria for the incidence question and the prognostic criteria for the risk factor question.
Question 1: What is the incidence of SUDEP in different epilepsy populations? Twelve Class I studies provided incidence rate data. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Imprecision in study findings resulted in moderate confidence in the evidence for SUDEP rates in childhood and low confidence in the evidence for SUDEP rates in adulthood and overall (table 1). Because of imprecision in the incidence study results with a lack of overlap of 95% confidence interval (CIs) between several comparable study populations, the guideline panel performed a randomeffects meta-analysis to provide summary measures of the absolute or relative risk of SUDEP. In addition, to explore reasons for heterogeneity in the absolute risk of SUDEP reported, the panel conducted a meta-analysis of subgroups of studies Table 1 Conclusions for sudden unexpected death in epilepsy (SUDEP) incidence People with epilepsy and their families prefer to be informed of the individual's risk for a catastrophic event such as SUDEP, even when the probability of the event is low. 18 This preference is subject to cultural influences. After being informed of an adverse event, people commonly overestimate the risk of that adverse event happening to them. 19 Such overestimation unduly increases anxiety related to an adverse event. Overestimation can be lessened by presenting the risk as the probability of both having and not having the event, 20 and by using numbers in addition to words 19 and frequencies rather than percentages to convey the risk. 21 Incidence recommendation 1: SUDEP incidence in children. Clinicians caring for children with epilepsy should inform the children's parents or guardians that (Level B for the following):
1. There is a rare risk of SUDEP. 2. In 1 year, SUDEP typically affects 1 in 4,500 children with epilepsy; in other words, annually, 4,499 of 4,500 children will not be affected by SUDEP.
Incidence recommendation 2: SUDEP incidence in adults.
Clinicians should inform adult persons with epilepsy that (Level B for the following):
1. There is a small risk of SUDEP. 2. In 1 year, SUDEP typically affects 1 in 1,000 adults with epilepsy; in other words, annually, 999 of 1,000 adults will not be affected by SUDEP. Rationale for recommendation 3. Our systematic review found that a major risk factor for SUDEP is the presence and frequency of generalized tonicclonic seizures (GTCS). For example, people with 3 or more GTCS per year have a 15-fold increased risk of SUDEP. This relative risk increase translates to an absolute risk of up to 18 deaths per 1,000 patientyears for people with frequent GTCS. 29 The large SUDEP risk increase from GTCS, coupled with epilepsy monitoring unit evidence 39 demonstrating that a GTCS was always the precipitating event of SUDEP, strongly suggests that GTCS are not just associated with SUDEP but, rather, are in the causal path to SUDEP. From this, it seems reasonable to infer that improved control of an individual's GTCS will result in a reduced risk of SUDEP. Thus, a reduction in SUDEP risk is an additional benefit to the many benefits resulting from improved seizure control.
As with all benefits associated with improved seizure control, the potential benefit of SUDEP risk reduction needs to be balanced with the risks and burdens associated with antiseizure therapies.
Recommendation 3. For persons with epilepsy who continue to experience GTCS, clinicians should continue to actively manage epilepsy therapies to reduce seizure occurrences and the risk of SUDEP while incorporating patient preferences and weighing the risks and benefits of any new approach (Level B).
Rationale for recommendation 4. GTCS are clear risk factors for SUDEP, and nocturnal seizures may also increase risk. These findings, in conjunction with the observation that postictal respiratory depression is a major mechanism in SUDEP, 39 suggest that unwitnessed nocturnal seizures and postictal respiratory depression can cause SUDEP.
Moreover, the presence in the bedroom of another individual at least 10 years of age and of normal intelligence is associated with a decreased SUDEP risk. These results imply that a bedroom observer could detect seizures, check on the patient, and provide sufficient stimulation to prevent respiratory arrest. This association does not indicate that these interventions directly mitigate the mechanism that causes SUDEP.
If it were in accordance with patient and family circumstances and values, nocturnal supervision could reduce SUDEP risk; however, providing nighttime observation might be overly burdensome and intrusive. Recommendation 4. For persons with frequent GTCS and nocturnal seizures, clinicians may advise selected patients and families, if permitted by their individualized epilepsy and psychosocial circumstances, to use nocturnal supervision or other nocturnal precautions, such as the use of a remote listening device, to reduce SUDEP risk (Level C).
Rationale for recommendation 5. One of the most consistent findings of this review is that many factors that are indicators of uncontrolled epilepsy, including having GTCS, having frequent GTCS, and the absence of seizure freedom, are strongly associated with SUDEP.
Usually, people with epilepsy and their families prefer to be informed of factors that are associated with an increased risk of a catastrophic event such as SUDEP. Patients are especially interested in factors that might reduce their risk even when a causal link between the factor and a reduction in risk has not been established. Knowledge of these risk factors might suggest behaviors that could modify the risk factors (e.g., improved therapy adherence 40 ), increase the person's sense of control, and reduce the anxiety that comes from awareness of the risk. Less severe seizure types, such as focal seizures or myoclonic seizures, are not proven to be associated with increased SUDEP risk, but individuals who have them often remain at risk for GTCS in the setting of therapy nonadherence. Therefore, therapy adherence to maintain freedom from GTCS is important even when an individual is not experiencing this severe seizure type.
Recommendation 5. Clinicians should inform patients with epilepsy that seizure freedom, particularly freedom from GTCS (which is more likely to occur with medication adherence), is strongly associated with a decreased risk of SUDEP (Level B).
Additional conclusions (no recommendations made). The evidence is low that the following factors are associated with altering SUDEP risk:
1. Nocturnal seizures (associated with increased risk) 2. Any specific antiepileptic drug (AED) (none associated specifically with increased risk) 3. Lamotrigine use in women (associated with increased risk) 4. Never having been treated with an AED (associated with increased risk) 5. Number of AEDs used overall (associated with increased risk) 6. Heart rate variability (not associated with increased risk) 1. Systematic methods should be developed to identify and report the incidence of SUDEP in different epilepsy populations in order to obtain a better understanding of the incidence and causes of this devastating condition. 2. Educational efforts are needed to improve the forensic knowledge of SUDEP among professionals such as medical examiners, coroners, and pathologists in order to help determine, and document on death certificates, the etiology in individuals, and in order to improve overall knowledge of this condition. 3. Research to identify preventable risk factors should be supported and encouraged so that future clinical trials will be conducted to reduce SUDEP occurrence. Of particular importance is to better understand (1) the relationship between the nature, severity, and duration of epilepsy and the occurrence of SUDEP and (2) whether current treatments affect the risk of developing SUDEP. 4. Because of (1) risks identified with frequent GTCS, (2) the fact that one study shows more SUDEP events occur in people in placebo arms of trials, and (3) increased SUDEP risk, serious consideration should be given to avoid assigning people with frequent GTCS to placebo for long periods.
DISCLAIMER Clinical practice guidelines, practice advisories, systematic reviews and other guidance published by the American Academy of Neurology and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information: (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); (3) addresses only the questions specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. AAN provides this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. 
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